Homemarket Newsstocks News

Alembic Pharma shares jump after USFDA approval for ulcerative colitis drug

Alembic Pharma shares jump after USFDA approval for ulcerative colitis drug

Alembic Pharma shares jump after USFDA approval for ulcerative colitis drug
Read Time
1 Min(s) Read
Profile image

By CNBCTV18.com Nov 2, 2022 5:04:49 PM IST (Published)

Alembic Pharma has a cumulative total of 174 ANDA approvals, including 150 final authorisations.

wealth-desk wealth-desk

Buy / Sell Alembic Pharma share

Recommended Articles

View All

Shares of Alembic Pharmaceuticals gained over 5.5 percent on Wednesday after the drug maker received final approval from the United States Food and Drug Administration (USFDA) for Mesalamine extended-release capsules UPS, 0.375g.
Mesalamine extended-release capsules are used for the treatment of ulcerative colitis and to prevent the remission of the disease in adults.
According to IQVIA data for the 12-month period ending June 2022, Mesalamine extended-release capsules USP, 0.375 g, have an estimated market size of US$ 133 million.
Alembic Pharma has a cumulative total of 174 ANDA approvals, including 150 final authorisations, from USFDA. Alembic Pharmaceuticals is a vertically integrated research and development pharmaceutical company, which manufactures and markets generic pharmaceutical products globally.
Shares of Alembic Pharmaceuticals ended at Rs 610.50, 5.65 percent higher on Wednesday.
The company will declare its September quarter results on November 11.
Check out our in-depth Market Coverage, Business News & get real-time Stock Market Updates on CNBC-TV18. Also, Watch our channels CNBC-TV18, CNBC Awaaz and CNBC Bajar Live on-the-go!